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Institute, Choma, Zambia; NV Organon, Oss, The Netherlands; Pharma Bio-Research International BV,
Zuidlaren, The Netherlands; ARTECEF BV, Maarssen, The Netherlands; Center for Sickle Cell Disease, Howard University,
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Abstract. The efficacy and safety of intramuscular artemotil (ARTECEF) was compared to intravenous quinine
in African children with cerebral malaria. This prospective block randomized open-label study was conducted at two
centers in Zambia. Subjects were children aged 0 to 10 years of age with cerebral malaria and a Blantyre Coma Score
of 2 or less. Ninety two children were studied; 48 received artemotil and 44 quinine. No significant differences in
survival, coma resolution time, neurologic sequelae, parasite clearance time, and fever resolution time were seen
between the two regimens. Rates for negative malaria smears one month after therapy were similar in both groups.
Artemotil was a well-tolerated drug in the 48 patients in this study. It appears to be at least therapeutically equivalent
to quinine for the treatment of pediatric cerebral malaria. It has the advantage of being able to be given intramuscularly
once daily for only five days.
INTRODUCTION
Malaria continues to be a major cause of childhood mor-
bidity and mortality in sub-Saharan Africa, and with the in-
creasing resistance ofPlasmodium falciparum to standard
drugs, effective new drugs to treat malaria and its compli-
cations are urgently needed. One promising group of drugs
is derived from the plantArtemisia annua L, which is used
as an herbal remedy in China for fever and malaria.1,2 Fol-
lowing the isolation of the active ingredient artemisinin (qin-
ghaosu) in 1972, various compounds have been developed
by chemical modification; four of these have now reached
the stage of pharmaceutical development for use in hu-
mans.3,4 One of these compounds, a semi-synthetic beta-
ethylether derivative of artemisinin originally known as-
arteether, but now renamed artemotil (ARTECEF), has been
developed collaboratively.5–7 The purpose of this program
was to provide an alternative drug for the treatment of severe
malaria, especially in areas where resistance is developing
to intravenous quinine, the standard treatment for cerebral
malaria. Using public funds for much of the drug’s devel-
opment, it was anticipated that the final cost of any regis-
tered drug would be within the financial reach of those in
the poorer and less developed countries of the world.
Following pre-clinical studies,6,8,9 artemotil was formulat-
ed in a sesame oil base for use as an intramuscular injection.
Phase I studies of the drug in healthy adult volunteers in The
Netherlands documented its tolerability, safety, and phar-
macokinetics (Jonkman JHG and others, unpublished data).10
Phase II studies in Thai adults with uncomplicated and se-
vere malaria showed safety and efficacy when used over a
five-day period with an initial loading dose (Peeters PAM
and others, unpublished data). Subsequently, a Phase III,
multicenter, open label, randomized comparative efficacy
study was proposed in African children with cerebral ma-
laria. The primary objective of the study was to compare the
efficacy of intramuscular artemotil versus intravenous qui-
nine in the treatment of cerebral malaria in children in terms
of survival. Secondary objectives included comparison of
other indicators of treatment response such as parasite clear-
ance time (PCT), fever clearance time (FCT), and coma re-
covery time (CRT). The presence of parasites at the 7, 14,
21 and 28 day post-treatment visits, and prevalence of neu-
rologic sequelae were also to be determined. In addition, the
study was designed to assess safety and tolerability of the
regimens. This report presents the results of this Phase III
study from two of the three centers that studied this drug in
African children with cerebral malaria.
MATERIALS AND METHODS
The study was conducted in accordance with the rules of
Good Clinical Practice and in compliance with the Decla-
ration of Helsinki revised in 1989. It was approved by the
Research and Ethics Committee of the University of Zambia
(Lusaka, Zambia) and the Secretariat of the Committee for
Research Involving Human Subjects, World Health Organi-
zation (Geneva, Switzerland). Informed written consent for
all participants was obtained from the parent or parents. The
project was undertaken at two centers in Zambia located in
communities in which malaria is endemic; the Macha Mis-
sion Hospital near Choma and the University Teaching Hos-
pital in Lusaka. The study was monitored at both sites by
Pharma Bio-Research International, B.V. (Zuidlaren, The
Netherlands), contracted as the study and safety monitor.
Enrollment and treatment. The study was carried out
between January 1996 and May 1997. Children aged 0–10
years presenting to either hospital with asexualP. falciparum
parasitemia and a Blantyre coma score11 of 2 or less with no
other cause for coma (normal cerebrospinal fluid, normogly-
cemic, more than 30 minutes since last convulsion) were
eligible for enrollment. Patients were excluded if there was
a prior history of any chronic illness, a clinical condition
compatible with chemical intoxication from traditional med-
icine, or black water fever (frank hemoglobinuria). Eligible
patients were then assigned a treatment group by opening a
sealed coded envelope that contained the results of a com-
puter-generated block randomization schedule. Baseline as-
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FIGURE 1. Flow diagram showing progress of patients through-
out the trial. QN  quinine. AR  artemotil. Rx  treatment. f/u
 follow-up.
sessments were performed including a complete physical ex-
amination, cerebrospinal fluid analysis, ECG, complete
blood count, glucose, renal and liver function tests, urinal-
ysis, and blood culture. Following Standard Operating Pro-
cedures for all patients, each child was initially given intra-
venous physiologic saline 10–15 mL/kg over 30 minutes for
rehydration, intramuscular phenobarbitone 10 mg/kg for sei-
zure prophylaxis, and whole blood (screened for HIV and
Hepatitis B) 15–20 mL/kg over 4 hours if the hematocrit
was less than 15%. Depending on the randomization code,
patients were given either 5 days of intramuscular artemotil
with an initial loading dose of 3.2 mg/kg and subsequent
daily doses of 1.6 mg/kg or intravenous quinine dihydro-
chloride using a loading dose of 20 mg/kg in 5% dextrose
over 4 hours followed by 10 mg/kg in 5% dextrose given
over 2 hours every 8 hours. Treatment with oral quinine
sulfate (10 mg/kg every eight hours) was commenced in-
stead of the intravenous quinine when the patient was able
to take oral medicine and had received a minimum of three
intravenous doses. The quinine therapy was continued for a
total of 7 days. Patients were treated using established guide-
lines12 with intensive nursing care including the determina-
tion of vital signs, coma score, and peripheral glucose every
four hours with malaria smears every eight hours.
Assessment and laboratory studies. The primary re-
sponse variable was survival rate. Secondary response var-
iables were coma recovery time (CRT), defined as the time
at which a Blantyre coma score of 5 was first attained and
maintained for 24 hours; fever clearance time (FCT) defined
as the time at which the first axillary temperature of 
37.5C was recorded preceding a 24 hour period in which
the temperature did not exceed this level; and parasite clear-
ance time (PCT) defined as the first negative malaria smear
with no subsequent positive smears in the following 24 hour
period. Patients were assessed on a twice-daily basis with a
detailed physical and neurological examination and a daily
detailed symptom review to determine any adverse effects
of the drugs. Hematological and biochemical parameters
were assessed on Days 0, 3, and 7. Following discharge at
Day 7, patients were seen at weekly intervals up to Day 28
for physical and neurological exams, hematological and bio-
chemical tests and a review of symptoms.
Peripheral smears for parasite quantification were ob-
tained from a fingerstick sample of blood from which both
a thick and thin smear were made on clean glass slides. The
slides were coded, stained with Giemsa stain and read in a
blinded fashion by two skilled microscopists. Results were
determined independently by counting and calculating the
percentage of parasitized red blood cells on a thin smear. If
parasitemia was less than 1%, the number of asexual para-
sites per 200 white blood cells on a thick smear were count-
ed. The results from the two microscopists were averaged
and multiplied by the appropriate red blood cell or white
blood cell count to determine the parasite density per micro-
litre of blood. Full blood count was determined by an au-
tomated counter (Cobas Micros, Roche Diagnostics, RSA)
and biochemical parameters by using spectrophotometric
kits (SIGMA Chemical, St. Louis, MO) with a spectropho-
tometer (Spectronics 20D, Milton Roy, NY). ECG was de-
termined before the start of therapy and on the last day of
therapy.
Statistical analysis. Malaria parasite concentrations
showed a log normal distribution and were logarithmically
transformed for statistical analysis. Data analysis was per-
formed with the Systat 7.0 (SPSS Inc., Chicago, IL) statis-
tical program using Student’s t-test for parametric and Mann-
Whitney U test for non-parametric continuous data and Fish-
er’s exact or Pearson’s chi-square test for proportions. All
tests were two-sided. Kaplan-Meier plots were determined
for primary and secondary variables. A logistic regression
model for the effect of treatment on survival was developed
using LogXact 2.1 (SPSS, Inc.), by first examining the effect
of the individual baseline variables on mortality. Those that
had a significance level of  0.1 were then incorporated into
a multivariate model, followed by a stepwise procedure re-
moving all covariates that no longer had a significance level
 0.1 in the multivariate model.
The original multicentre study was designed to demon-
strate a lack of difference in the survival rate among arte-
motil recipients compared to recipients of the standard qui-
nine treatment. A survival rate of at least 85% was consid-
ered the approximate survival rate in children with cerebral
malaria who receive standard treatment. Based on this as-
sumption, we planned to recruit a total of 480 patients as-
suming an estimated rate of 15% withdrawals and post-en-
rollment exclusions.
RESULTS
A total of 95 children were enrolled in the study at the
two Zambian sites; 46 at the rural Macha Mission Hospital
and 49 at University Teaching Hospital in Lusaka. As shown
in Figure 1, the three who died before therapy was begun
were excluded from analysis, leaving 44 in the quinine group
and 48 in the artemotil group. The comparison of baseline
clinical and demographic variables between those who re-
ceived quinine and those who received artemotil showed ad-
equate randomization (Table 1). Although children random-
ized to the quinine group had a significantly increased rate
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TABLE 1
Baseline characteristics of study patients (mean  SD)
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SD  standard deviation.
FIGURE 2. Kaplan-Meier plot showing survival curve of 92 pa-
tients receiving quinine or artemotil.
TABLE 2
Survival rates













UTH  University Teaching Hospital.
of seizures before admission as well as higher mean baseline
parasitemia counts, other indicators of more severe malaria
were not more common in the quinine group. Children at
the rural hospital were more likely to be younger and sicker
with higher parasite counts than those at the urban hospital
but were adequately randomized between the two drug study
groups.
Survival rates. Table 2 shows survival rates for patients
from both centers and for the combined treatment groups.
There was no difference in survival rates between the two
treatment groups. Those children receiving treatment with
quinine had a survival rate of 80% (95% C.I., 67% to 92%)
while those receiving artemotil had a survival rate of 79%
(95% C.I., 67% to 91%) (P  0.964). Figure 2 demonstrates
the remarkable similarity of the Kaplan-Meier survival
curves between artemotil and quinine. A logistic regression
model was developed with stratification by study site using
covariates of age, history of seizures, log of malaria parasites
at Time 0, and duration of coma prior to treatment. With this
model, the adjusted odds ratio for death in those receiving
artemotil was 0.89 the odds in the quinine group (95% C.I.,
0.3 to 3.0, P  0.96).
Other indicators of efficacy. Secondary variables for this
study were PCT, FCT, and CRT among survivors. Results
are shown in Table 3. For 9 survivors (6 receiving artemotil
and 3 receiving quinine), coma resolution times could not
be calculated due to persistent severe neurologic sequelae
lasting for more than 7 days. For these patients, the coma
recovery time was censored at 168 hours and this result was
used for statistical analysis purposes. One patient did not
have adequate recording of parasite counts to enable deter-
mination of a PCT and two patients had no fever after ad-
mission, thus preventing calculation of FCT. While those
treated with quinine had a shorter mean CRT (44 hours ver-
sus 61 hours) and a shorter mean FCT (34 hours versus 50
hours) neither of these were statistically significant differ-
ences. The mean PCT was only marginally different (not
significant), being 57 hours for the quinine treatment group
and 53 hours for the artemotil treatment group.
Parasite clearance was also evaluated by graphing the per-
cent change in parasites from the start of therapy and cal-
culating 50% and 95% clearance times for each patient. The
mean 50% clearance time was similar for both treatments:
14.9 hours for quinine and 15.4 hours for artemotil. The
mean 95% clearance time was 31.9 hours for quinine and
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TABLE 3
























CRT  coma resolution time; PCT  parasite clearance time; FCT  fever clearance
time; QN  quinine; AR  artemotil; SD  standard deviation.
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Note: Some patients had more than one neurologic sequelae.
TABLE 4
Proportion of survivors with no neurologic sequelae
Treatment group
Proportion (%) with no neurologic sequelae
Day 7 Day 14 Day 21 Day 28
Quinine (survivors with follow-up)









29.2 hours for artemotil, with no significant difference be-
tween the two treatment modalities. It should be noted that
the higher mean baseline parasite counts in the quinine group
makes interpretation of the data difficult.
For both regimens, the rates for having a negative malaria
smear were calculated at 7, 14, 21 and 28 days after begin-
ning therapy, and were not significantly different. At Day 7,
32/35 (91%) of those receiving quinine had a negative ma-
laria smear compared to 34/38 (90%) in the artemotil group.
Patients were not discharged to a malaria-free transmission
zone, and most did not have access to malaria preventive
measures such as mosquito nets or chemoprophylaxis, so
that a subsequent positive malaria smear did not differentiate
between recrudescence or a reinfection. The proportion of
negative smears in the artemotil group was greater than that
of the quinine group at every point after Day 7, but this was
not a significant difference.
Results of neurological follow up among survivors and
the proportion with no neurologic sequelae or deficits are
shown in Table 4. The categories and frequencies of sequelae
at follow-up visits are shown in Table 5. No statistically
significant differences were seen between the two treatment
groups in any of these parameters, although by Day 28, of
those who had received quinine, 3/24 (11%) had residual
neurologic sequelae compared to 5/34 (15%) of those who
had received artemotil. Additional documentation of the time
taken after recovery from coma to regain the milestones of
eating, drinking, sitting, standing and walking were available
from the rural Macha Hospital study site. No significant dif-
ferences in these parameters were seen between the two
treatment groups.
Adverse events. Not including death, there were a total
of 82 adverse events recorded in 36/48 (75%) of the patients
receiving artemotil and 61 adverse events recorded in 34/44
(77%) of the patients receiving quinine. Most of these events
were consistent with severe malaria and the expected mul-
tiorgan involvement of the illness. Table 6 shows the type
and frequency of adverse events in all categories where more
than a total of 3 adverse events was recorded. Comparison
of hematological and biochemical parameters at Days 0, 3,
7, 14, 21 and 28 between the two treatment groups revealed
no significant differences. Pre and post-treatment ECGs were
assessed for any arrhythmia or changes in QT interval. No
abnormalities were seen.
DISCUSSION
This is the first reported clinical trial on the use of arte-
motil in African children with cerebral malaria. The multi-
centre study (of which this report is a part) intended to re-
cruit a total of 480 patients; however the two study sites in
Zambia were able to recruit only 95 patients. While malaria
has been on the increase in this country in recent years, this
study defined cerebral malaria as a Blantyre coma score of
 2, excluding many cases of severe malaria. Despite the
limited number of patients studied, the results indicate that
artemotil is at least as efficacious as standard quinine ther-
apy. The adjusted odds ratio for death in the artemotil group
was 0.9 times the odds in the quinine group, with a 95%
confidence interval of 0.3 to 3.0 (P  0.96). The CRT, PCT
and FCT were also not significantly different between the
two treatment groups.
Various published reports have documented the efficacy
of other artemisinin derivatives for the treatment of P. fal-
ciparum malaria,13,14 including the treatment of cerebral ma-
laria using artemether in children.15,16 While parasite clear-
ance tended to be faster in the present study in the artemotil
group as has been reported in other studies of artemisinin
derivatives,17 the data from this study did not reach statistical
significance. In addition, the higher mean baseline parasite
counts in the quinine group make interpretation of the data
difficult. This study did not compare artemotil to artemether.
It would appear that it has no clear advantage over arte-
mether other than the fact that it is formulated in sesame
seed oil rather than peanut oil, theoretically leading to less
likely exposure to aflatoxins.
A concern of possible neurotoxicity from artemisinin de-
rivatives18–21 and the wisdom of using this drug in patients
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who are already neurologically compromised by cerebral
malaria has been raised. Studies in dogs have shown dose-
related damage to certain brain-stem nuclei, especially from
artemether and arteether (now called artemotil) when given
by intramuscular injection in an oily base.20 Thus, the present
study was designed to monitor the neurological status of
each patient carefully, determining the rate of neurological
sequelae22 with one center also documenting the times it took
to regain various milestones. Analysis of the data generated
from this small study shows no significant difference in neu-
rological sequelae between those receiving artemotil com-
pared to those receiving conventional quinine. While not sta-
tistically significant, the finding that at Day 28, of those re-
ceiving quinine, only 11% had neurologic sequelae com-
pared to 15% of those receiving artemotil warrants close
monitoring in future studies since this may be due to a subtle
effect of artemotil therapy. Despite this, these results are in
agreement with a recent Cochrane systematic review of pub-
lished and unpublished randomized studies of artemisinin
derivatives compared to quinine used to treat cerebral ma-
laria. No significant difference in neurological sequelae were
found.4
The recording of adverse events during the study also doc-
umented that 10 children experienced aphasia, speech dis-
orders, or deafness during or after treatment in the artemotil
group compared to 6 in the quinine group. These adverse
events should be carefully monitored in the future to deter-
mine whether they are related to the type of therapy. It
should also be pointed out that since the current study was
not designed to detect subtle neurological effects of the
drugs such effects could have occurred without being de-
tected.
The development of resistance by P. falciparum to current
drugs for malaria makes it imperative to develop new drugs.
Artemotil appears to be effective even when P. falciparum
strains develop resistance to other drugs.23,24 Although artem-
isinin derivatives have been used for many years in China,
resistance to these drugs has been slow to develop, making
it likely that they will have a relatively long usefulness com-
pared to other recently developed drugs such as halofan-
trine.25,26 Despite the relative lack of resistance to artemisinin
derivatives noted to date, the cure rates using these drugs
may be affected by the observed inter-individual variability
in drug pharmacokinetics.27 While there are several reasons
for this variability, absorption from an intramuscular injec-
tion site may be unpredictable, especially in children who
are comatose with little muscle activity. Two of the artemotil
deaths in our study had parasitemia at the time of death, one
at 38 hours and the other at 140 hours after the start of
therapy. Whether this represented resistance to artemotil or
poor absorption of the drug is not known since levels of
artemotil and its metabolites in the patients’ serum samples
were not available. Recrudescence of parasitemia after treat-
ment with artemisinin derivatives is possible if the course of
therapy is shorter than 5 to 7 days. Distinguishing between
recrudescence and re-infection is difficult without the use of
parasite molecular fingerprinting techniques. These were not
performed in this study.
Apart from the low incidence of resistance, another po-
tentially important yet underrated benefit of the artemisinin
derivatives over more commonly used drugs such as quinine
and mefloquine, is their effect on limiting gametocyte pro-
duction.28 If artemisinin derivatives were to be used for the
treatment of severe malaria in children, it is possible that
these children with sometimes extremely high parasite
counts and gametocyte carriage rates would no longer be a
community source of gametocytes after treatment, and thus
lead to a decrease in community transmissibility of malaria.29
As malaria continues to exert its toll on the lives of chil-
dren in sub-Saharan Africa, it is imperative that new treat-
ment modalities are found that will decrease the unnecessary
suffering and the more than 1 million annual deaths asso-
ciated with this disease. rtemotil has been shown to be
efficacious for the treatment of pediatric cerebral malaria in
this study. Its mode of delivery, once-daily intramuscular
injections, lends its usefulness to situations that are found in
much of rural Africa where access to intravenous delivery
of drugs is not available. The use of intramuscular artemotil
as an alternative drug to intravenous quinine for pediatric
cerebral malaria may be a valuable addition to the limited
armamentarium currently available in a large part of Africa.
Further studies are indicated to asses this possibility and
evaluate its safety as compared to intravenous quinine.
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